HIGHLIGHTS
- who: Thomas J. Velenosi from the Published in partnership with The Hormel Institute, University of Minnesota have published the research work: Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer, in the Journal: (JOURNAL) of February/15,/1993
- what: The authors employed TNBC-PDX models known to be sensitive or resistant to doxorubicin as an innovative pharmacometabolomics approach to identify and characterize urinary metabolic biomarkers of doxorubicin effectiveness. The authors propose that high-baseline levels of SAT1 and diacetylspermine production mask the induction by doxorubicin at physiological levels.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.